Product Information
Registration Status: ActiveSIN06732P
POTASSIUM CITRATE MIXTURE BP is approved to be sold in Singapore with effective from 1991-12-19. It is marketed by ICM PHARMA PTE LTD, with the registration number of SIN06732P.
This product contains Citric Acid 5% w/v, and Potassium Citrate 30% w/v in the form of SOLUTION. It is approved for ORAL use.
This product is manufactured by ICM PHARMA PTE LTD in SINGAPORE.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
Toxicity
ORAL (LD50): Acute: 5040 mg/kg [Mouse]. 3000 mg/kg [Rat].
Active Ingredient/Synonyms
2-Hydroxytricarballylic acid | 3-Carboxy-3-hydroxypentane-1,5-dioic acid | Citric Acid, Anhydrous | Citronensäure | Citric Acid |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.
Indication
For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
Mechanism of Action
After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.
Toxicity
LD50 (dog): Intravenous 176 mg/kg.
Active Ingredient/Synonyms
tripotassium citrate | Potassium Citrate |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.